Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polymyxin b sulfate + lidocaine hydrochloride + bacitracin zinc + neomycin
- Development stage
- Unknown
- Lead developer
- Kenvue
- Modality
- Small Molecules, Peptides
- Administration
- Topical
01
Overview
**Polymyxin b sulfate + lidocaine hydrochloride + bacitracin zinc + neomycin** is a fixed-dose topical first-aid combination of three antibacterial agents and the local anesthetic lidocaine. Bacitracin inhibits bacterial cell-wall precursor recycling through binding to undecaprenyl pyrophosphate; neomycin is an aminoglycoside that impairs bacterial protein synthesis through the 30S ribosomal subunit; and polymyxin B disrupts susceptible Gram-negative bacterial outer membranes by binding lipopolysaccharide. Lidocaine reversibly blocks voltage-gated sodium channels to provide local analgesia. The combination is supplied as an OTC ointment for prevention of infection and temporary relief of pain or discomfort in minor cuts, scrapes, and burns. It is not a treatment for painful urethritis; that indication applies to lidocaine hydrochloride jelly products rather than this four-component topical antibiotic formulation.
- Brand names
- Neosporin Plus LidocaineTriple Antibiotic Plus Lidocaine
- Other names
- neomycin and polymyxin B sulfates + bacitracin zinc + lidocaine ointmenttriple antibiotic plus lidocaine ointment
02
Targets
30S A-site (Bacterial ribosomal 30S A-site)Lipid A phosphate (Lipid A phosphate groups)C55-PP (Undecaprenyl pyrophosphate)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on polymyxin b sulfate + lidocaine hydrochloride + bacitracin zinc + neomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polymyxin b sulfate + lidocaine hydrochloride + bacitracin zinc + neomycin.